{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:17:18Z","timestamp":1792685838865,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.ajkd.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:12:45Z","timestamp":1766247165000},"page":"573-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7778-292X","authenticated-orcid":false,"given":"Howard","family":"Trachtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Eddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1053\/j.ajkd.2025.10.013_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D\u2019Agati","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.013_bib4","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1681\/ASN.2017020174","article-title":"FSGS as an Adaptive response to growth-induced podocyte stress","volume":"28","author":"Nishizono","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.kint.2023.11.018","article-title":"Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today","volume":"105","author":"Trachtman","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00441-021-03454-3","article-title":"Immune-mediated entities of (primary) focal segmental glomerulosclerosis","volume":"385","author":"Braun","year":"2021","journal-title":"Cell Tissue Res"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.013_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.34067\/KID.0000000000000499","article-title":"Minimal change disease and FSGS are a spectrum of a single disease within immune-mediated nephrotic syndrome","volume":"5","author":"Sim","year":"2024","journal-title":"Kidney360"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.013_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2215\/CJN.07180622","article-title":"The immune system and idiopathic nephrotic syndrome","volume":"17","author":"Campbell","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.013_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/atm-22-3670","article-title":"Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors","volume":"11","author":"Rashmi","year":"2023","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.013_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm.4242","article-title":"Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease","volume":"23","author":"Hahm","year":"2017","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.013_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1247606","article-title":"Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis","volume":"14","author":"Salfi","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.013_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.013_bib15","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1681\/ASN.2019020152","article-title":"Contributions of rare gene variants to familial and sporadic FSGS","volume":"30","author":"Wang","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.013_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ackd.2014.06.001","article-title":"Familial FSGS","volume":"21","author":"Pollak","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla","year":"2024","journal-title":"Kidney Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib18","doi-asserted-by":"crossref","first-page":"e907","DOI":"10.1542\/peds.2006-2164","article-title":"Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2)","volume":"119","author":"Hinkes","year":"2007","journal-title":"Pediatrics"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib19","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.013_bib20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.0000000000000249","article-title":"The clinical utility of genetic testing in the diagnosis and management of adults with chronic kidney disease","volume":"34","author":"Dahl","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","article-title":"Obesity-related glomerulopathy: an emerging epidemic","volume":"59","author":"Kambham","year":"2001","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.013_bib22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.0000000000000357","article-title":"Spatiotemporal landscape of kidney tubular responses to glomerular proteinuria","volume":"35","author":"Faivre","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.013_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1681\/ASN.2021060751","article-title":"Serum protein exposure activates a core regulatory program driving human proximal tubule injury","volume":"33","author":"Lidberg","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib26","article-title":"Interventions for focal segmental glomerulosclerosis in adults","volume":"2","author":"Hodson","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.013_bib27","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2019.08.019","article-title":"Steroid-associated side effects in patients with primary proteinuric kidney disease","volume":"4","author":"Oh","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.013_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1681\/ASN.2015060672","article-title":"Kr\u00fcppel-like factor 15 mediates glucocorticoid-induced restoration of podocyte differentiation markers","volume":"28","author":"Mallipattu","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.013_bib29","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1681\/ASN.2018030324","article-title":"Podocyte-specific induction of Kr\u00fcppel-like factor 15 restores differentiation markers and attenuates kidney injury in proteinuric kidney disease","volume":"29","author":"Guo","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.013_bib30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1681\/ASN.0000000000000460","article-title":"A small molecule agonist of Kr\u00fcppel-like factor 15 in proteinuric kidney disease","volume":"35","author":"Guo","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.013_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117692559","article-title":"Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis: a systematic review and meta-analysis of the literature","volume":"4","author":"Laurin","year":"2017","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib32","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.013_bib33","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfu097","article-title":"Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience","volume":"29","author":"Ramachandran","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.07110615","article-title":"Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.013_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213203","article-title":"Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment","volume":"14","author":"Angeletti","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00467-020-04695-0","article-title":"Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review","volume":"36","author":"Malakasioti","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10289","key":"10.1053\/j.ajkd.2025.10.013_bib38","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.10.013_bib39","article-title":"Predicting calcineurin inhibitor response in glomerular diseases (abstract TH-OR97)","volume":"35","author":"Eddy","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1681\/ASN.0000000520","article-title":"Long-term outcomes of rituximab-treated adult patients with podocytopathies","volume":"36","author":"Gauckler","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib41","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/0886022X.2013.794687","article-title":"Mycophenolate mofetil for primary focal segmental glomerulosclerosis: systematic review","volume":"35","author":"Lau","year":"2013","journal-title":"Ren Fail"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.013_bib42","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","article-title":"Treatment of idiopathic FSGS with adrenocorticotropic hormone gel","volume":"8","author":"Hogan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.013_bib43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/CS20200016","article-title":"Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling","volume":"134","author":"Qiao","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.013_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib45","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.013_bib47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41581-020-0286-5","article-title":"Integrated multi-omics approaches to improve classification of chronic kidney disease","volume":"16","author":"Eddy","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.013_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","article-title":"Phase I trial of adalimumab in focal segmental glomerulosclerosis: II: report of the FONT (Novel Therapies for Resistant FSGS) Study Group","volume":"55","author":"Joy","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2025.10.013_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2369-12-8","article-title":"Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design","volume":"12","author":"Trachtman","year":"2011","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.kint.2022.10.023","article-title":"Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis","volume":"103","author":"Mariani","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.013_bib51","doi-asserted-by":"crossref","first-page":"284","DOI":"10.34067\/KID.0000000635","article-title":"Precision medicine proof-of-concept study of a TNF inhibitor in FSGS and treatment-resistant minimal change disease","volume":"6","author":"Trachtman","year":"2025","journal-title":"Kidney360"},{"issue":"316","key":"10.1053\/j.ajkd.2025.10.013_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1053\/j.ajkd.2025.10.013_bib53","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.10.013_bib54","article-title":"Framework for precision medicine in focal segmental glomerulosclerosis: translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids","author":"Eddy","year":"20250226","journal-title":"medRxiv"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI82592","article-title":"A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis","volume":"126","author":"Yu","year":"2016","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib56","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.0000000000000069","article-title":"Rapid progression of focal segmental glomerulosclerosis in patients with high-risk APOL1 genotypes","volume":"18","author":"Kallash","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.013_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.kint.2018.05.022","article-title":"JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis","volume":"94","author":"Tao","year":"2018","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.10.013_bib59","article-title":"Inflammatory and JAK-STAT pathways as shared molecular targets for ANCA-associated vasculitis and nephrotic syndrome","author":"Eddy","year":"2018","journal-title":"bioRxiv"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.013_bib60","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"708","key":"10.1053\/j.ajkd.2025.10.013_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8226","article-title":"Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome","volume":"15","author":"Ding","year":"2023","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.013_bib62","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1681\/ASN.0000000000000355","article-title":"Gene therapy for glomerular disease","volume":"35","author":"Saleem","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.013_bib63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.013_bib64","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.013_bib65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib66","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","article-title":"Treatment of patients with IgA nephropathy: a call for a new paradigm","volume":"107","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.013_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.013_bib68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.akdh.2024.03.009","article-title":"Focal segmental glomerulosclerosis","volume":"31","author":"Suresh","year":"2024","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.013_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.013_bib70","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ekir.2023.09.026","article-title":"TRPC6 inhibitor BI 764198 in focal segmental glomerulosclerosis: phase 2 study design","volume":"8","author":"Trachtman","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"10528","key":"10.1053\/j.ajkd.2025.10.013_bib71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(25)02255-X","article-title":"TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomized, placebo-controlled, phase 2 trial of BI 764198","volume":"407","author":"Trachtman","year":"2026","journal-title":"Lancet"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625012107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625012107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:15:57Z","timestamp":1773908157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625012107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0272638625012107"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}